SAN DIEGO--(BUSINESS WIRE)--Today, DermTech, Inc., a privately held commercial stage molecular diagnostic company developing gene expression tests for skin cancer, announced its non-invasive platform technology is highlighted in Nature’s November issue of BioPharma Dealmakers (http://bit.ly/1kSNst7). DermTech is the first to offer gene expression tests to the clinical dermatologist that can be used as an aid in diagnosis with specimens collected using an adhesive patch rather than scalpel. DermTech’s platform technology can be used as a stand alone diagnostic or a diagnostic aid for difficult to identify skin conditions such as skin cancers. DermTech’s innovative platform can also be used to support clinical drug development both to stratify patients and to monitor clinical response. DermTech has current collaborations with Biogen and Astra Zeneca/ MedImmune.
BioPharma Dealmakers focuses on showcasing innovative medical technology companies seeking partners, as well as exploring the deal making trends of the growing medical technology industry. November’s issue focuses on the dermatology market which is forecast to reach $19 billion in 2015.
DermTech is a commercial stage molecular dermatology company developing non-invasive gene expression tests to aid the clinical diagnosis of skin cancer and other skin conditions. DermTech operates a CLIA licensed laboratory located in the company’s La Jolla, CA headquarters. DermTech’s technology allows the analysis of skin biopsy samples collected non-invasively using an adhesive patch. DermTech provides highly accurate, objective information to physicians to improve care and reduce costs. Current dermatologic diagnosis is primarily based on subjective visual pattern recognition that is prone to error and results in a substantial number of unnecessary surgical procedures. For additional information visit: www.dermtech.com.